As such, it is tempting to speculate that these SpCas9 ADAR-targeting gRNAs could be effective in enhancing anti-tumor immune responses in the context of different therapeutic delivery modalities (e.g., lipid nanoparticles, viral vectors, RNP). The gene discussed is RNPC3; the disease is neoplasm.